THU0162 WHICH PERSISTENCE OF METHOTREXATE AFTER INITIATION OF THE 1ST BDMARD IN RHEUMATOID ARTHRITIS? THE RETRO-RIC2 STUDY. (June 2019)

• Record Type: Journal Article
• Authors: Baudens, Guy; Adrien, Tonione; Salmon, Jean-Hugues; Letarouilly, Jean-Guillaume; Zinovieva, Elena; Herman-Demars, Hélène; Gervais, Elisabeth; Flipo, Rene-Marc
• Is Part Of: Annals of the rheumatic diseases. Volume 78(2019)Supplement 2
• Page Start: 354
• Page End: 355
• Publication Date: 2019-06
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2019-eular.7476
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: ACR and EULAR guidelines recommend to prescribe bDMARDs and particularly TNFi in combination with methotrexate (MTX). However, the MTX observence in RA is poor, mainly due to side effect and some bDMARDs (IL6 receptor antagonist) are almost as effective in monotherapy. Objectives: to evaluate MTX use (dosage, route of administration…) in RA after initiation of the first bDMARD. Methods: RETRO-RIC2 is a multicentric retrospective study. Were included all patients with RA under MTX therapy at the initiation of the 1 st bDMARD from October 2008 to September 2016. The main criteria is the persistence of MTX after 1 and 2 years. Results: 409 patients were included : mean-age = 58.9 years, female 69%, RF positive 76% and ACPA positive 83%, mean RA duration = 13.14y and mean DAS28-ES=4.48. The mean duration of previous MTX therapy = 32 months (mean dose = 16.2mg/w). At the inclusion MTX was administrated by oral route in 52% and subcutaneous in 48%. The first bDMARD was a TNF inhibitor in 70% At inclusion, 1.2% of the patients switch from oral route MTX for subcutaneous; inversely in only 0.2% the SC route was switched for oral administration. The results are presented in table 1 and Figure 1 . V-1 = last previous visit before inclusion Conclusion: In almost all patients MTX dose and route of administration are unchanged at the initiation of the first bDMARD in RA. With a 2 years follow up 49.9% of MTX dose were reduced and MTX was stopped in 2.9%. At 2 years MTX route of administration is oral for 64% of the patients and s/c for 36%. Acknowledgement: None Disclosure of Interests: Guy Baudens Grant/research support from: Financial Grant from NordicPharma, Consultant for: Roche SAS, TONIONE Adrien Grant/research support from: Grant from NordicPharma, Jean-Hugues Salmon Speakers bureau: Janssen Novartis, Jean-Guillaume Letarouilly: None declared, Elena Zinovieva Employee of: Nordic Pharma, Hélène Herman-Demars Employee of: Nordic Pharma, Elisabeth Gervais Grant/research support from: Roche, Pfizer, Consultant for: Bristol-Myers Squibb, UCB, Rene-Marc Flipo Consultant for: Advisory board: Bristol-Myers Squibb